Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone

International Journal of Hematology

Volumn 79, Issue 4, 2004, Pages 311-321

  Armitage, James O ^a   Tobinai, Kensei ^b   Hoelzer, Dieter ^c   Rummel, Mathias J ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

2 CdA; Cladribine; Indolent lymphoma; Mitoxantrone

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DIARRHEA; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; HYPOXEMIA; LEUKOPENIA; LYMPHOCYTOMA; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; POLYNEUROPATHY; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; VIRUS INFECTION; VOMITING;

EID: 2942578934     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04050     Document Type: Review

References (74)

1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
4. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-720.
5. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
6. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.
7. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.
8. Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219-1227.
9. Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10:489-497.
10. Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:52-60.
11. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470-1480.
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
13. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
14. Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK Trial [abstract]. Blood. 2002;100:161a. Abstract 604.
15. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
16. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
17. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
18. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999;26(suppl 14):88-96.
19. Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma [abstract]. Blood. 2003;102:28a. Abstract 87.
20. Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JEA. The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients [abstract]. Blood. 2003;102:273a. Abstract 245.
21. Rohatiner AZ, Gregory WM, Peterson BA, Smalley RV. A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 1998;17:4a. Abstract 11.
22. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:445-450.
23. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
24. Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev. 2000;14:1-13.
25. Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640-645.
26. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
27. O'Connor OA, Wright J, Moskowitz C, Macgregor-Cortelli B, Straus D, Horse-Grant D. Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphoma [abstract]. Proc Am Soc Clin Oncol. 2003;22:2566. Abstract 2277.
28. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
29. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
30. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
31. Wierda WG, O'Brien S, Faderl S, et al. Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination [abstract]. Blood. 2003;102:100a. Abstract 373.
32. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.
33. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157-4164.
34. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-806.
35. Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C. Non-gastric MALT lymphomas: a survey of 369 European patients: the International Extranodal Lymphoma Study Group (IELSG) [abstract]. Ann Oncol. 2000;11:4499. Abstract 4440.
36. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol. 1999;10:637-645.
37. Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Muller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet. 2002;360:547-548.
38. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747-2753.
39. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40.
40. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340:952-956.
41. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74:5677-5681.
42. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77:6865-6869.
43. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.
44. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80:2203-2209.
45. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol. 1993;11:679-689.
46. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.
47. Barton K, Larson RA, O'Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol. 1992;10:1821.
48. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10:371-377.
49. Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:788-792.
50. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995;86:1710-1716.
51. Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies: Cladribine Study Group. Jpn J Clin Oncol. 1997;27:146-153.
52. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23:250-257.
53. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12:2216-2228.
54. Shimoyama M. Diagnostic criteria and classification of clinical sub-types of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
55. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80:587-592.
56. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738.
57. Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma [see comments]. Blood. 1996;87:906-911.
58. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.
59. Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol. 2003;77:512-517.
60. Tobinai K, Kobayashi Y, Morishima Y. Prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphoma: results of Japanese phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;20:2228b. Abstract 2664.
61. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454-2460.
62. Rummel MJ, Chow KU, Jager E, et al. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma. 1999;35:129-138.
63. Hickish T, Serafinowski P, Cunningham D, et al. 2′ -Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer. 1993;67:139-143.
64. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol. 1995;6:49-52.
65. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res. 1995;1:385-390.
66. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol. 1992;10:1514-1518.
67. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995;13:989-995.
68. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896.
69. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997;15:1803-1810.
70. Chow KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro-2′deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymphoma. 2000;36:559-567.
71. Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:2139-2144.
72. Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:850-858.
73. Betticher DC, Ratschiller D, Hsu Schmitz SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1998;9:721-726.
74. Robak T, Gora-Tybor J, Urbanska-Rys H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32:359-363.